Michels Family Financial LLC acquired a new stake in Medtronic plc (NYSE:MDT - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 7,065 shares of the medical technology company's stock, valued at approximately $564,000.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Olstein Capital Management L.P. raised its holdings in Medtronic by 8.0% in the 4th quarter. Olstein Capital Management L.P. now owns 94,000 shares of the medical technology company's stock valued at $7,509,000 after acquiring an additional 7,000 shares during the last quarter. Empowered Funds LLC grew its holdings in Medtronic by 2.7% in the 4th quarter. Empowered Funds LLC now owns 105,822 shares of the medical technology company's stock valued at $8,453,000 after buying an additional 2,778 shares in the last quarter. Caprock Group LLC grew its holdings in Medtronic by 12.6% in the 4th quarter. Caprock Group LLC now owns 47,767 shares of the medical technology company's stock valued at $3,849,000 after buying an additional 5,363 shares in the last quarter. Synergy Asset Management LLC increased its stake in shares of Medtronic by 107.1% in the 4th quarter. Synergy Asset Management LLC now owns 227,802 shares of the medical technology company's stock worth $19,353,000 after acquiring an additional 117,809 shares during the last quarter. Finally, Equitable Trust Co. grew its holdings in shares of Medtronic by 91.7% in the fourth quarter. Equitable Trust Co. now owns 39,645 shares of the medical technology company's stock valued at $3,167,000 after purchasing an additional 18,968 shares during the period. Hedge funds and other institutional investors own 82.06% of the company's stock.
Analyst Upgrades and Downgrades
MDT has been the subject of several analyst reports. Needham & Company LLC reissued a "hold" rating on shares of Medtronic in a research note on Monday, May 19th. Truist Financial decreased their price target on Medtronic from $93.00 to $90.00 and set a "hold" rating on the stock in a research note on Friday, April 11th. Robert W. Baird cut their price objective on Medtronic from $94.00 to $92.00 and set a "neutral" rating on the stock in a report on Thursday, May 22nd. UBS Group boosted their price target on shares of Medtronic from $85.00 to $95.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 19th. Finally, Mizuho lowered their price objective on shares of Medtronic from $100.00 to $98.00 and set an "outperform" rating for the company in a research note on Thursday, May 22nd. One research analyst has rated the stock with a sell rating, nine have given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $96.07.
Get Our Latest Stock Analysis on MDT
Medtronic Stock Up 1.2%
Shares of MDT traded up $0.94 during mid-day trading on Thursday, reaching $82.18. The company's stock had a trading volume of 2,854,806 shares, compared to its average volume of 6,803,630. The company's 50 day moving average is $84.46 and its 200 day moving average is $86.28. The stock has a market cap of $105.40 billion, a PE ratio of 24.98, a price-to-earnings-growth ratio of 2.22 and a beta of 0.81. Medtronic plc has a 12-month low of $75.96 and a 12-month high of $96.25. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.90 and a quick ratio of 1.39.
Medtronic (NYSE:MDT - Get Free Report) last announced its quarterly earnings results on Wednesday, May 21st. The medical technology company reported $1.62 EPS for the quarter, topping the consensus estimate of $1.58 by $0.04. The firm had revenue of $8.93 billion for the quarter, compared to analyst estimates of $8.81 billion. Medtronic had a net margin of 12.83% and a return on equity of 14.07%. Medtronic's revenue for the quarter was up 3.9% compared to the same quarter last year. During the same period last year, the business earned $1.46 EPS. Equities analysts anticipate that Medtronic plc will post 5.46 EPS for the current fiscal year.
Medtronic Increases Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 11th. Stockholders of record on Friday, June 27th will be issued a $0.71 dividend. This is an increase from Medtronic's previous quarterly dividend of $0.70. This represents a $2.84 annualized dividend and a dividend yield of 3.46%. The ex-dividend date is Friday, June 27th. Medtronic's dividend payout ratio is presently 78.45%.
Medtronic Profile
(
Free Report)
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.
Read More
Before you consider Medtronic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medtronic wasn't on the list.
While Medtronic currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
